1. Home
  2. BEAM vs TRMK Comparison

BEAM vs TRMK Comparison

Compare BEAM & TRMK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$34.32

Market Cap

3.0B

Sector

Health Care

ML Signal

HOLD

Logo Trustmark Corporation

TRMK

Trustmark Corporation

HOLD

Current Price

$46.00

Market Cap

2.6B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
BEAM
TRMK
Founded
2017
1889
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
2.6B
IPO Year
2019
1994

Fundamental Metrics

Financial Performance
Metric
BEAM
TRMK
Price
$34.32
$46.00
Analyst Decision
Buy
Hold
Analyst Count
12
2
Target Price
$50.75
$44.50
AVG Volume (30 Days)
2.1M
366.0K
Earning Date
05-06-2026
04-28-2026
Dividend Yield
N/A
2.26%
EPS Growth
82.31
1.93
EPS
N/A
0.95
Revenue
$24,000.00
N/A
Revenue This Year
N/A
$9.82
Revenue Next Year
$33.77
$4.86
P/E Ratio
N/A
$48.78
Revenue Growth
33.33
N/A
52 Week Low
$15.60
$35.96
52 Week High
$36.88
$46.61

Technical Indicators

Market Signals
Indicator
BEAM
TRMK
Relative Strength Index (RSI) 59.75 59.29
Support Level $26.96 $43.28
Resistance Level $36.44 N/A
Average True Range (ATR) 2.18 0.90
MACD 0.34 0.14
Stochastic Oscillator 68.09 75.62

Price Performance

Historical Comparison
BEAM
TRMK

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

About TRMK Trustmark Corporation

Trustmark Corp is a bank holding company. Through its subsidiaries, the company operates as a financial services organization providing banking and other financial solutions in Alabama, Florida, Mississippi, Tennessee, and Texas. Its principal products and services include Commercial Banking, Consumer Banking, Mortgage Banking, Insurance, Wealth Management and Trust Services, and others. The company is managed along two operating segments: General Banking and Wealth Management. The General Banking segment, which generates the majority of the revenue, provides all traditional banking products and services, including loan deposits, and also consists of internal operations.

Share on Social Networks: